FGFR1c/β-Klotho Agonistic AltibodyTM to Enhance Clustering & Functional Activation

• Illustrate how structural modeling informed the transition from a conventional bispecific format to a 2+1 configuration, boosting receptor activation from 30% to 70%
• Share optimization strategies across linker design, Fab vs. scFv formats, and IgG subclass backbones to enhance clustering efficiency and functional activity
• Highlight the iterative design process, including Fc modifications to balance effector function, and lessons learned for applying structure-based design to complex antibody engineering challenges

Speakers:

Naga Suhasini Avvaru

Associate Director

Regeneron Pharmaceuticals